Physician profile
Daniel J Hyman
NPI 1346335023
$2,968.79
in general payments reported to CMS, 2019-2025
33 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $195 · 2021: $299 · 2022: $197 · 2023: $524 · 2024: $941 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $318.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $272.56 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $189.53 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $187.16 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $171.27 | 2021-2025 | |
| Lilly USA, LLC | $161.71 | 2022-2025 | Zepbound, Mounjaro, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.72 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $152.46 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $126.88 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $124.99 | 2024 | |
| Glaxosmithkline, LLC. | $124.27 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Ucb, INC. | $114.65 | 2023 | Bimzelx |
| Amgen INC. | $104.52 | 2019-2024 | Repatha, Otezla |
| Regeneron Healthcare Solutions, INC. | $103.97 | 2020 | |
| Abbvie INC. | $98.20 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $97.04 | 2024 | Inspire |
| Sanofi Pasteur INC. | $69.60 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $68.99 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.33 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $34.69 | 2021 | |
| Dexcom, INC. | $30.42 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $27.41 | 2022-2024 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $24.21 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.32 | 2024 | Caplyta |
| Verona Pharma, INC. | $17.93 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $16.50 | 2023 | |
| Xeris Pharmaceuticals, INC. | $16.33 | 2023 | Gvoke Hypopen |
| Almatica Pharma LLC | $16.20 | 2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $16.04 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $15.78 | 2024 | |
| Amarin Pharma, INC. | $15.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.35 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.